Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review
S Chatterji, E Krzoska, CW Thoroughgood… - The Lancet …, 2023 - thelancet.com
… that male and female breast cancer differ in their molecular landscapes. In this systematic
review, we consolidated all existing prognostic biomarker data in male breast cancer spanning …
review, we consolidated all existing prognostic biomarker data in male breast cancer spanning …
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression
K Chatzopoulos, AR Collins, S Sotiriou… - Head and Neck …, 2020 - Springer
… underlying gene copy number alterations and we evaluated … Chromosome 17 copy numbers
that are detected by FISH can … in breast cancer patients, even without concurrent ERBB2 …
that are detected by FISH can … in breast cancer patients, even without concurrent ERBB2 …
[HTML][HTML] Dual-color dual-hapten in situ hybridization (D-DISH)–Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer
PK Gajaria, S Tambe, T Pai, A Patil… - Indian Journal of …, 2020 - journals.lww.com
… SPEC ERBB2 probe specific for the chromosomal region … We evaluated the HER2/neu gene
amplification status by D-… the discrepancy in evaluating chromosome 17 abnormalities in our …
amplification status by D-… the discrepancy in evaluating chromosome 17 abnormalities in our …
[HTML][HTML] ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution
A Yu, S Luikart, G Huang, S Han, J Zhao… - Cancer medicine …, 2020 - ncbi.nlm.nih.gov
… alone (eg, chromosome 17 ERBB2 gene locus), resulting in … most common abnormalities
in GEA and breast cancers, none … the value of CMA in GEA evaluation. Our study calls for the …
in GEA and breast cancers, none … the value of CMA in GEA evaluation. Our study calls for the …
[HTML][HTML] Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature)
B Smolarz, AZ Nowak, H Romanowicz - Cancers, 2022 - mdpi.com
… gene, located on chromosome 17, is a suppressor gene that … of developing breast cancer
regardless of menopausal status. … These mutations, including NF1 loss and ERBB2 activating …
regardless of menopausal status. … These mutations, including NF1 loss and ERBB2 activating …
[HTML][HTML] Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
ZS Lima, M Ghadamzadeh, FT Arashloo… - Journal of hematology & …, 2019 - Springer
… in breast cancer can be an effective therapeutic approach for developing novel drugs. This
systematic review discusses gene mutations linked to breast cancer, … status/quality of life [40]. …
systematic review discusses gene mutations linked to breast cancer, … status/quality of life [40]. …
[HTML][HTML] Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer
S Chatterji, JM Niehues, M van Treeck… - … Breast Cancer, 2023 - nature.com
… of BC, we evaluated the efficacy of attMIL pipelines in predicting ERα and PR status in both
… which could be predictive of the hormone receptor status of the tumor in H&E-stained slides. …
… which could be predictive of the hormone receptor status of the tumor in H&E-stained slides. …
[HTML][HTML] HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
A Grenda, K Wojas-Krawczyk, T Skoczylas… - BMC …, 2020 - Springer
… Amplification of HER2 gene (ERBB2) and overexpression of … DNA located at the centromere
of chromosome 17 (17p11.1-q11.1)… evaluation in liquid biopsy in patients with breast cancer …
of chromosome 17 (17p11.1-q11.1)… evaluation in liquid biopsy in patients with breast cancer …
[HTML][HTML] Molecular perspective on targeted therapy in breast cancer: a review of current status
B Demir Cetinkaya, C Biray Avci - Medical Oncology, 2022 - Springer
… directly against molecular abnormalities or tumor cells that cause cancer development. The
… the tyrosine kinase of HER1, HER2 / ErbB2, and EGFR, subsequently prevents the receptor …
… the tyrosine kinase of HER1, HER2 / ErbB2, and EGFR, subsequently prevents the receptor …
[PDF][PDF] Metastatic and pathophysiological characteristics of breast cancer with emphasis on hereditary factors
A Faramarzi, MG Jahromi… - Cent. Asian J. Med …, 2021 - researchgate.net
… environmental factors of breast cancer are Geographical status, … ErbB2 gene amplification
is associated with … P53 is located on the short arm of chromosome 17, and its deletion is …
is associated with … P53 is located on the short arm of chromosome 17, and its deletion is …